Literature DB >> 22593237

Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines.

Christine M Hughes1, Frances K Newman, Whitni B Davidson, Victoria A Olson, Scott K Smith, Robert C Holman, Lihan Yan, Sharon E Frey, Robert B Belshe, Kevin L Karem, Inger K Damon.   

Abstract

Possible smallpox reemergence drives research for third-generation vaccines that effectively neutralize variola virus. A comparison of neutralization assays using different substrates, variola and vaccinia (Dryvax and modified vaccinia Ankara [MVA]), showed significantly different 90% neutralization titers; Dryvax underestimated while MVA overestimated variola neutralization. Third-generation vaccines may rely upon neutralization as a correlate of protection.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22593237      PMCID： PMC3393368          DOI： 10.1128/CVI.00056-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  9 in total

1.  Dose-dependent neutralizing-antibody responses to vaccinia.

Authors:  Robert B Belshe; Frances K Newman; Sharon E Frey; Robert B Couch; John J Treanor; Carol O Tacket; Lihan Yan
Journal:  J Infect Dis       Date:  2004-01-23       Impact factor: 5.226

2.  Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence.

Authors:  H Meyer; G Sutter; A Mayr
Journal:  J Gen Virol       Date:  1991-05       Impact factor: 3.891

3.  Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.

Authors:  Jens Vollmar; Nathaly Arndtz; Karl M Eckl; Torben Thomsen; Barbara Petzold; Luis Mateo; Bernd Schlereth; Amanda Handley; Lynette King; Vanessa Hülsemann; Maria Tzatzaris; Karin Merkl; Niels Wulff; Paul Chaplin
Journal:  Vaccine       Date:  2005-11-28       Impact factor: 3.641

Review 4.  The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses.

Authors:  G Antoine; F Scheiflinger; F Dorner; F G Falkner
Journal:  Virology       Date:  1998-05-10       Impact factor: 3.616

5.  characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak.

Authors:  Kevin L Karem; Mary Reynolds; Zach Braden; Gin Lou; Nikeva Bernard; Joanne Patton; Inger K Damon
Journal:  Clin Diagn Lab Immunol       Date:  2005-07

6.  Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine.

Authors:  Frances K Newman; Sharon E Frey; Tamara P Blevins; Mahendra Mandava; Andres Bonifacio; Lihan Yan; Robert B Belshe
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

7.  Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.

Authors:  Sharon E Frey; Frances K Newman; Jeffrey S Kennedy; Vera Sobek; Francis A Ennis; Heather Hill; Lihan K Yan; Paul Chaplin; Jens Vollmar; Bernard R Chaitman; Robert B Belshe
Journal:  Vaccine       Date:  2007-10-26       Impact factor: 3.641

8.  Clonal vaccinia virus grown in cell culture as a new smallpox vaccine.

Authors:  Richard Weltzin; Jian Liu; Konstantin V Pugachev; Gwendolyn A Myers; Brie Coughlin; Paul S Blum; Richard Nichols; Casey Johnson; John Cruz; Jeffrey S Kennedy; Francis A Ennis; Thomas P Monath
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

9.  Evaluation of smallpox vaccines using variola neutralization.

Authors:  Inger K Damon; Whitni B Davidson; Christine M Hughes; Victoria A Olson; Scott K Smith; Robert C Holman; Sharon E Frey; Frances Newman; Robert B Belshe; Lihan Yan; Kevin Karem
Journal:  J Gen Virol       Date:  2009-04-01       Impact factor: 3.891
  9 in total
  9 in total

1.  Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.

Authors:  Sharon E Frey; Patricia L Winokur; Heather Hill; Johannes B Goll; Paul Chaplin; Robert B Belshe
Journal:  Vaccine       Date:  2014-03-06       Impact factor: 3.641

2.  Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.

Authors:  Sharon E Frey; Patricia L Winokur; Robert A Salata; Samer S El-Kamary; Christine B Turley; Emmanuel B Walter; Christine Mhorag Hay; Frances K Newman; Heather R Hill; Ying Zhang; Paul Chaplin; Magdalena Tary-Lehmann; Robert B Belshe
Journal:  Vaccine       Date:  2013-05-09       Impact factor: 3.641

3.  Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations.

Authors:  M B Townsend; M S Keckler; N Patel; D H Davies; P Felgner; I K Damon; K L Karem
Journal:  J Virol       Date:  2012-11-07       Impact factor: 5.103

4.  Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections.

Authors:  Iuliia Gilchuk; Pavlo Gilchuk; Gopal Sapparapu; Rebecca Lampley; Vidisha Singh; Nurgun Kose; David L Blum; Laura J Hughes; Panayampalli S Satheshkumar; Michael B Townsend; Ashley V Kondas; Zachary Reed; Zachary Weiner; Victoria A Olson; Erika Hammarlund; Hans-Peter Raue; Mark K Slifka; James C Slaughter; Barney S Graham; Kathryn M Edwards; Roselyn J Eisenberg; Gary H Cohen; Sebastian Joyce; James E Crowe
Journal:  Cell       Date:  2016-10-20       Impact factor: 41.582

5.  Serological Immunity to Smallpox in New South Wales, Australia.

Authors:  Valentina Costantino; Mallory J Trent; John S Sullivan; Mohana P Kunasekaran; Richard Gray; Raina MacIntyre
Journal:  Viruses       Date:  2020-05-18       Impact factor: 5.048

6.  Serological study of vaccinia virus reservoirs in areas with and without official reports of outbreaks in cattle and humans in São Paulo, Brazil.

Authors:  Marina Gea Peres; Thais Silva Bacchiega; Camila Michele Appolinário; Acácia Ferreira Vicente; Susan Dora Allendorf; João Marcelo Azevedo Paula Antunes; Sabrina Almeida Moreira; Emerson Legatti; Clóvis Rinaldo Fonseca; Edviges Maristela Pituco; Liria Hiromi Okuda; José Carlos de Figueiredo Pantoja; Fernando Ferreira; Jane Megid
Journal:  Arch Virol       Date:  2013-06-13       Impact factor: 2.574

Review 7.  Challenges and Achievements in Prevention and Treatment of Smallpox.

Authors:  Sharon Melamed; Tomer Israely; Nir Paran
Journal:  Vaccines (Basel)       Date:  2018-01-29

8.  Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.

Authors:  Sharon E Frey; Anna Wald; Srilatha Edupuganti; Lisa A Jackson; Jack T Stapleton; Hana El Sahly; Samer S El-Kamary; Kathryn Edwards; Harry Keyserling; Patricia Winokur; Wendy Keitel; Heather Hill; Johannes B Goll; Edwin L Anderson; Irene L Graham; Christine Johnston; Mark Mulligan; Nadine Rouphael; Robert Atmar; Shital Patel; Wilbur Chen; Karen Kotloff; C Buddy Creech; Paul Chaplin; Robert B Belshe
Journal:  Vaccine       Date:  2015-07-02       Impact factor: 4.169

Review 9.  Human Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention.

Authors:  Eskild Petersen; Anu Kantele; Marion Koopmans; Danny Asogun; Adesola Yinka-Ogunleye; Chikwe Ihekweazu; Alimuddin Zumla
Journal:  Infect Dis Clin North Am       Date:  2019-04-11       Impact factor: 5.905
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.